Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005

Abstract

Recent cardiovascular trials funded by for-profit organizations are more likely to report positive findings than trials funded by not-for-profit organizations, as are trials using surrogate rather than clinical end points. Trials jointly funded by not-for-profit and for-profit organizations appear to report positive findings at a rate approximately midway between rates observed in trials supported solely by one or the other of these entities.

The association of funding source on effect size in randomized controlled trials: 2013–2015 – a cross-sectional survey and meta-analysis

“…Our findings are in line with earlier studies demonstrating an association between for-profit-funded research and a more favorable outcome [1, 3, 5, 15]; however, these studies were based on data published 10–15 years ago. Previous research has been focused on specific medical fields, such as cardiovascular research [3], nutrition [16], or drug trials [5].…”

How Can the Evidence from Global Large-scale Clinical Trials for Cardiovascular Diseases be Improved?

“…This difference was statistically significant (p = 0.012, 2-sided Fisher's exact test), indicating that industry-funded trials were significantly more likely to report statistically significant differences favoring target interventions compared with references. This result is consistent with the findings of previous reports [5-11], showing that industry-funded trials tended to produce results in favor of target interventions compared with references.…”

The Impact of Source of Funding on the Outcome of Clinical Trials in India

“…The result of this assignment is in line with the previous studies in the literature such as Davidson (1986), Yaphe et al (2001), Kjaergard and Als-Nielsen (2002), Bhandari et al (2004), Ridker and Torres (2006), Bero et al (2007) and Bourgeois et al (2010). They showed that there exists a positive relationship between pharmaceutical industries’ funding (profit organisations’ funding) of clinical trials and its success.…”